CFTR and COVID-19: Dysfunctional CFTR altered the susceptibility to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, resulting in the reduced viral entry and replication in cystic fibrosis cells [15], and CFTR inhibitors displayed antiviral activity against SARS-CoV-2 in vitro [16].